TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
0.7962
+0.0330 (4.32%)
At close: Aug 7, 2026, 4:00 PM EDT
0.8003
+0.0041 (0.51%)
After-hours: Aug 7, 2026, 7:34 PM EDT

TScan Therapeutics Revenue

TScan Therapeutics had revenue of $982.00K in the quarter ending March 31, 2026, a decrease of -54.77%. This brings the company's revenue in the last twelve months to $9.14M, up 106.65% year-over-year. In the year 2025, TScan Therapeutics had annual revenue of $10.33M with 266.65% growth.

Revenue (ttm)
$9.14M
Revenue Growth
+106.65%
P/S Ratio
5.70
Revenue / Employee
$65,727
Employees
139
Market Cap
52.03M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 202510.33M7.51M266.65%
Dec 31, 20242.82M-18.23M-86.62%
Dec 31, 202321.05M7.51M55.52%
Dec 31, 202213.54M3.39M33.47%
Dec 31, 202110.14M9.06M834.65%
Dec 31, 20201.09M--
Dec 31, 2019---

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
Karyopharm Therapeutics151.12M
Xilio Therapeutics53.48M
Immutep5.28M
RenovoRx1.49M
aTyr Pharma190.00K
INmune Bio50.00K
Revenue Rankings